News
Skye Bioscience Inc (SKYE) reports significant advancements in clinical trials and financial stability, despite increased ...
Q2 2025 Management View Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for ...
Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback